Interim Topline Data From Trial Of Investigational Oral GED-0301 In Patients With Active Crohn’s Disease Anoounced Celgene

Celgene Announces Interim Topline Data from Trial of Investigational Oral GED-0301 in Patients with Active Crohn’s Disease.The trial, CD-001, is an ongoing study evaluating three different treatment regimens of GED-0301 in a 12-week treatment phase, followed by an observation phase up to 52 weeks (off treatment).

Link:
www.businesswire.com/news/home/20160912005688/en/Celgene-Announces-Interim-Topline-Data-Trial-Investigational